Download PDF
J Neurol Surg A Cent Eur Neurosurg 2023; 84(02): 212-215
DOI: 10.1055/s-0041-1728768
Case Report

Spontaneous Hematomyelia Associated with the Use of Non–vitamin K Antagonist

Moon Soo Park 
1   Department of Orthopedic Surgery, Hallym University Sacred Heart Hospital, Medical College of Hallym University, Gyeonggi-do, Republic of Korea
,
Seong-Hwan Moon
2   Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea
,
Seung Bo Jang
1   Department of Orthopedic Surgery, Hallym University Sacred Heart Hospital, Medical College of Hallym University, Gyeonggi-do, Republic of Korea
,
Jeoung Woo Kim
1   Department of Orthopedic Surgery, Hallym University Sacred Heart Hospital, Medical College of Hallym University, Gyeonggi-do, Republic of Korea
,
Paul S. Sung
3   Doctoral Program in Physical Therapy, The Herbert H. and Grace A. Dow College of Health Professions, Central Michigan University, Mount Pleasant, Michigan, United States
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Vitamin K antagonists have been frequently prescribed as anticoagulants with the potential side effect of spontaneous hematomyelia with a poor prognosis. However, to our knowledge, there has been no report of spontaneous hematomyelia combined with the use of a non–vitamin K antagonist. A 63-year-old man presented with left leg weakness, impaired sensation, and urinary retention while taking rivaroxaban (non–vitamin K antagonist) for 4 months for atrial fibrillation. Anticoagulant agents were discontinued. Methylprednisolone pulse therapy was administered without surgical hematoma evacuation. Three months after the initial development of the hematomyelia, the symptoms improved to grade 5 for both lower extremities, and there was complete recovery in sensory and urinary functions. This might be the first description of a complete recovery of neurologic deficits without hematoma evacuation in spontaneous hematomyelia patients caused by non–vitamin K antagonist therapy.

Keywords

anticoagulant - rivaroxaban - spinal intramedullary hematoma


Publication History

Received: 25 April 2020

Accepted: 26 November 2020

Article published online:
14 June 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Papo I, Luongo A. Massive intramedullary hemorrhage in a patient on anticoagulants. Case report. J Neurosurg Sci 1974; 18 (04) 268-270
    PubMedGoogle Scholar
  • 2 Brandt M. Spontaneous intramedullary haematoma as a complication of anticoagulant therapy. Acta Neurochir (Wien) 1980; 52 (1–2): 73-77
    CrossrefPubMedGoogle Scholar
  • 3 Constantini S, Ashkenazi E, Shoshan Y, Israel Z, Umansky F. Thoracic hematomyelia secondary to coumadin anticoagulant therapy: a case report. Eur Neurol 1992; 32 (02) 109-111
    CrossrefPubMedGoogle Scholar
  • 4 Cakirer S, Basak M, Galip GM. Cervical hematomyelia secondary to oral anticoagulant therapy: case report. Neuroradiology 2001; 43 (12) 1087-1088
    CrossrefPubMedGoogle Scholar
  • 5 Friedland ML, Wittels EG. Spinal cord haemorrhage following herpes zoster: a possible complication of warfarin therapy. Postgrad Med J 1982; 58 (675) 39-40
    CrossrefPubMedGoogle Scholar
  • 6 Pisani R, Carta F, Guiducci G, Silvestro C, Davini MD. Hematomyelia during anticoagulant therapy. Surg Neurol 1985; 24 (05) 578-580
    CrossrefPubMedGoogle Scholar
  • 7 Pullarkat VA, Kalapura T, Pincus M, Baskharoun R. Intraspinal hemorrhage complicating oral anticoagulant therapy: an unusual case of cervical hematomyelia and a review of the literature. Arch Intern Med 2000; 160 (02) 237-240
    CrossrefPubMedGoogle Scholar
  • 8 Famularo G, Sajeva MR, Gasbarrone L. Warfarin-associated hematomyelia. Intern Med 2014; 53 (06) 623-626
    CrossrefPubMedGoogle Scholar
  • 9 Robbins M, Verghese J. Acute painless progressive quadriplegia associated with warfarin use. J Am Geriatr Soc 2007; 55 (05) 799-800
    CrossrefPubMedGoogle Scholar
  • 10 Beynon C, Olivares A, Gumbinger C, Younsi A, Zweckberger K, Unterberg AW. Management of spinal emergencies in patients on direct oral anticoagulants. World Neurosurg 2019; 131: e570-e578
    CrossrefPubMedGoogle Scholar
  • 11 Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53 (01) 1-16
    CrossrefPubMedGoogle Scholar
  • 12 Chikuda H, Yasunaga H, Takeshita K. et al. Mortality and morbidity after high-dose methylprednisolone treatment in patients with acute cervical spinal cord injury: a propensity-matched analysis using a nationwide administrative database. Emerg Med J 2014; 31 (03) 201-206
    CrossrefPubMedGoogle Scholar
  • 13 Bracken MB, Shepard MJ, Holford TR. et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997; 277 (20) 1597-1604
    CrossrefPubMedGoogle Scholar
  • 14 Bamps S, Decramer T, Vandenbussche N. et al. Dabigatran-associated spontaneous acute cervical epidural hematoma. World Neurosurg 2015; 83 (02) 257-258
    CrossrefPubMedGoogle Scholar
  • 15 Mathais Q, Esnault P, Cruc M, Bernard C, Prunet B, Gaillard PE. Spontaneous cervical spinal epidural hematoma associated with dabigatran. World Neurosurg 2018; 112: 264-266
    CrossrefPubMedGoogle Scholar
  • 16 Ismail R, Zaghrini E, Hitti E. Spontaneous spinal epidural hematoma in a patient on rivaroxaban: case report and literature review. J Emerg Med 2017; 53 (04) 536-539
    CrossrefPubMedGoogle Scholar
  • 17 Jaeger M, Jeanneret B, Schaeren S. Spontaneous spinal epidural haematoma during Factor Xa inhibitor treatment (Rivaroxaban). Eur Spine J 2012; 21 (Suppl. 04) S433-S435
    CrossrefPubMedGoogle Scholar
  • 18 Castillo JM, Afanador HF, Manjarrez E, Morales XA. Non-traumatic spontaneous spinal subdural hematoma in a patient with non-valvular atrial fibrillation during treatment with rivaroxaban. Am J Case Rep 2015; 16: 377-381
    CrossrefPubMedGoogle Scholar